NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD
3.57
+0.06 (+1.71%)
The current stock price of ONCO is 3.57 USD. In the past month the price decreased by -12.93%. In the past year, price decreased by -75.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.64 | 338.09B | ||
AMGN | AMGEN INC | 14.37 | 160.37B | ||
GILD | GILEAD SCIENCES INC | 14.06 | 135.34B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.97B | ||
REGN | REGENERON PHARMACEUTICALS | 12.41 | 59.38B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.34B | ||
ARGX | ARGENX SE - ADR | 99.6 | 34.97B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.42B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.69B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.52B | ||
INSM | INSMED INC | N/A | 19.76B | ||
NTRA | NATERA INC | N/A | 19.58B |
Onconetix Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO US
Employees: 12
Phone: 15136204101
The current stock price of ONCO is 3.57 USD. The price increased by 1.71% in the last trading session.
The exchange symbol of ONCONETIX INC is ONCO and it is listed on the Nasdaq exchange.
ONCO stock is listed on the Nasdaq exchange.
ONCONETIX INC (ONCO) has a market capitalization of 1.86M USD. This makes ONCO a Nano Cap stock.
ONCONETIX INC (ONCO) currently has 12 employees.
ONCONETIX INC (ONCO) has a resistance level at 5.11. Check the full technical report for a detailed analysis of ONCO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONCO does not pay a dividend.
ONCONETIX INC (ONCO) will report earnings on 2025-08-27.
ONCONETIX INC (ONCO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2779.82).
ChartMill assigns a fundamental rating of 1 / 10 to ONCO. ONCO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ONCO reported a non-GAAP Earnings per Share(EPS) of -2779.82. The EPS increased by 66.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -306.22% | ||
ROE | -1272.8% | ||
Debt/Equity | 1.98 |
ChartMill assigns a Buy % Consensus number of 43% to ONCO. The Buy consensus is the average rating of analysts ratings from 6 analysts.